LYEL Lyell Immunopharma
- 0.916
- -0.001-0.07%
Lyell Immunopharma News
Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(3.93%)
Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report
Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(3.93%)
Lyell Immunopharma | 3: Initial statement of beneficial ownership of securities-Director Ramachandra Sumant
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Ramachandra Sumant
Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%), etc.
Lyell Immunopharma | 8-K: Current report
Lyell Immunopharma | 8-K: Current report
Lyell Immunopharma | 10-Q: Q2 2024 Earnings Report
Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
Lyell Immunopharma | 8-K: Current report
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director NELSEN ROBERT
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Klausner Richard
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director RIEFLIN WILLIAM JL
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director NABEL ELIZABETH G
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director BRAWLEY OTIS W
Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Director FRIEDMAN CATHY
Lyell Immunopharma | 8-K: Current report
Analysis
Price Target
No Data
No Data